Psyence Biomedical (PBM) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shuttle Pharmaceuticals (SHPH) has outperformed Psyence Biomedical (PBM) over the past year, losing 78.2% versus a loss of 94.9%. Shuttle Pharmaceuticals is the larger company by market cap ($16.6 million vs $15.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBM | SHPH |
|---|---|---|
| Share price | $2.97 | $3.49 |
| Market cap | $15.80M | $16.63M |
| 1-day change | +3.85% | -10.51% |
| YTD return | -89.90% | -80.61% |
| 1-year return | -94.90% | -78.19% |
| EPS (TTM) | $-12.56 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.01M | $-11.72M |
| 52-week high | $73.44 | $44.40 |
| 52-week low | $1.92 | $2.58 |
| Distance from 52-week high | -95.96% | -92.14% |
| Average volume | 61.93K | 41.80K |
| Shares outstanding | 5.32M | 4.76M |
| Employees | 12 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SHPH has outperformed PBM by 16.7 percentage points over the past year.
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PBM vs SHPH FAQ
Which is bigger, Psyence Biomedical or Shuttle Pharmaceuticals?
Shuttle Pharmaceuticals (SHPH) is larger, with a market capitalization of $16.63M compared with $15.80M for Psyence Biomedical (PBM).
Which stock has performed better over the past year, PBM or SHPH?
SHPH returned -78.19% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Psyence Biomedical and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.